Valuation dashboard for Cellectar Biosciences, Inc. (CLRB) with P/E N/A, P/B 0.98, EV/EBITDA 0.59 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $2.35, CLRB has negative trailing earnings (P/E not meaningful) and an ROE of -165.71%. Market capitalisation stands at $19M.
Balance sheet quality for CLRB: current ratio of 3.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.98 |
| EV / EBITDA | 0.59 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $4.39 |
| vs Current Price | +86.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CLRB | Cellectar Biosciences, Inc. | $19M | 0.98 | -165.7% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.35 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -165.71% |
| Return on Invested Capital | -74.93% |
| Return on Assets | -60.93% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AEON · BOLT · CING · EVGN · IMNN · LYRA · MBIO
Explore sector: Healthcare · Biotechnology
More sections of CLRB: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks